Aflac Incorporated

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

Aflac Incorporated (NYSE:AFL) Q4 2022 Earnings Call Transcript

AI-generated analysis

πŸ“ˆ Aflac reported adjusted earnings per diluted share of $5.67 for 2022, excluding foreign currency impacts, marking its second-best year in company history.

πŸ’° Aflac Japan achieved a strong profit margin of 24.9% and maintained high persistency at 94.1% despite pandemic-related challenges.

πŸ‡―πŸ‡΅ Sales in Japan rose 10.8% in the second half of 2022, driven by new cancer insurance products and successful product updates.

🀝 Aflac Japan plans to launch a new cancer insurance product through the Japan Post Group starting in April 2023.

πŸ‡ΊπŸ‡Έ The U.S. business delivered a 17.4% sales increase in the fourth quarter, reaching its largest quarterly premium in company history.

πŸ“‰ Investment income remained stable in Q4, though the alternative investment portfolio posted a $21 million loss due to market pressures.

πŸ’Έ Management deployed $2.4 billion in capital for share repurchases in 2022, complementing dividends to return $3.4 billion to shareholders.

πŸ“‰ Aflac Japan aims to reach Β₯80 billion in production by the 2025–2026 period as it recovers from pandemic disruptions and platform changes.

πŸ”„ The company is actively digitizing operations, targeting 80% digital application submission and over 40% digital claims processing by 2025.

⚠️ U.S. persistency weakened slightly in 2022 due to lapses in large group accounts, though the core individual business remained stable.

πŸ“‰ COVID-19 was downgraded to seasonal flu status in Japan starting mid-May, expected to normalize claims volumes and benefit ratios.

🏦 Aflac maintains a strong capital position with a combined U.S. Risk-Based Capital (RBC) ratio north of 60%, allowing for future optimization.

πŸ“‰ The alternative investment portfolio generated $103 million in income year-to-date despite the Q4 loss, following an exceptional 2021.

πŸ”„ CEO Dan Amos and COO Fred Crawford emphasized a unified global strategy with Fred spending most of 2023 based in Japan to drive local growth.

πŸ“‰ A new critical illness lump-sum rider will be added to cancer policies in April to support sales recovery through the Japan Post channel.

πŸ’Ή Higher interest rates in Japan are expected to positively impact Aflac's earnings surplus ratio (ESR) and provide investment opportunities.

Bullish Signals
  • Aflac reported adjusted earnings per diluted share of $5.67 for 2022, ranking as its second-best year in company history following a record 2021.
  • Aflac Japan achieved an extremely strong profit margin of 24.9% and maintained a persistency rate of 94.1% in 2022.
  • U.S. sales increased by 17.4% in the fourth quarter, reflecting the largest amount of quarterly premium in Aflac U.S. history.
  • The company delivered $3.4 billion back to shareholders in 2022 through a combination of dividends and share repurchases.
  • Aflac has increased its dividend for 40 consecutive years and recently reiterated a first-quarter dividend increase of 5%.
  • In the U.S., expansion businesses including network dental, vision, group life, and disability saw sales increases of 98% and 75% respectively for the full year.
  • The U.S. individual business recorded 97% premium persistency in its life and disability platform.
  • Aflac deployed $2.4 billion in capital to repurchase 39.2 million shares in 2022, demonstrating confidence in its stock value.
  • Stress tests confirmed that Aflac's core capital ratios (RBC, SMR, and ESR) remain well above minimum thresholds even under moderate and severe recession scenarios.
  • Aflac maintains the highest return on capital and the lowest cost of capital among industry peers.
  • The company successfully launched new cancer insurance products in collaboration with Japan Post Group, expected to drive intermediate-term growth.
  • Digital adoption initiatives are progressing, with applications submitted digitally rising from 30% to approximately 50%.
Risk Factors
  • U.S. persistency declined by 260 basis points, driven largely by large account lapses in group voluntary accounts which represent 15% of earned premium.
  • The alternative investment portfolio posted a $21 million loss in the quarter compared to $127 million in gains the prior year due to anticipated weakness and public equity market correlation.
  • Japan Post's distribution platform is recovering in a linear fashion rather than a step function, causing muted growth rates for Aflac Japan's production platform.
  • Digital adoption faces significant hurdles as many Japanese financial service companies never went remote during COVID and remain tied to paper processing, hindering the industry-wide shift to digital claims adjudication.
  • A new cancer insurance rider developed with Japan Post Group is subject to regulatory approval by the Financial Services Agency (FSA) before it can be launched in April.
Full Analysis
Aflac Incorporated reported strong financial results for the fourth quarter of 2022, with adjusted earnings per diluted share excluding foreign currency impacts reaching $5.67 for the full year, marking the company's second-best year on record following a record 2021. In Japan, the company achieved an extremely strong profit margin of 24.9% and maintained high persistency at 94.1%, driven by resilient operations despite lingering pandemic effects. Sales in Japan rose 10.8% in the second half of the year, including an 11.4% increase in the fourth quarter, fueled by the August launch of "Associates of Wings," a new cancer insurance product. The company also announced plans to begin selling this cancer insurance product through the Japan Post Group in April, alongside a serious disease rider developed in collaboration with Japan Post, subject to regulatory approval. In the United States, Aflac delivered a solid profit margin of 20.4% in the fourth quarter, supported by lower incurred benefits and higher adjusted net income. The U.S. business saw a significant sales increase of 17.4% in the fourth quarter, reflecting the largest quarterly premium in company history and a full-year sales growth of 16.1%. This growth was driven by improved productivity among agents and brokers, as well as contributions from acquired platforms including dental, vision, group life, and disability insurance. Expansion businesses within these platforms showed robust growth, with network dental and vision sales up 98% and premier life and disability sales up 75% for the full year. Regarding capital management and shareholder returns, Aflac declared a dividend increase of 5% for the first quarter, marking the 40th consecutive year of dividend increases. In 2022, the company deployed $2.4 billion in share repurchases, totaling $3.4 billion returned to shareholders when combined with dividends. The executive team highlighted a focus on revitalizing distribution channels in Japan, particularly through partnerships with Japan Post and Dai-Ichi Life Insurance, while also advancing digital transformation initiatives aimed at increasing digital application and claims processing rates from current levels of 50% and 10% respectively to target goals of 80% and over 40%. Looking ahead to 2023, management noted that while Japan Post's distribution platform is recovering in a linear fashion rather than a step function, the company remains committed to its long-term production targets. The U.S. business continues to face some challenges with persistency, particularly in group voluntary accounts where large account lapses contributed to a 260-basis-point decline in overall persistency; however, the company has established a dedicated office to address these issues through product development and technology solutions. Investment results remained stable with investment income offset by higher hedge costs and anticipated weakness in alternative investments, which posted a $21 million loss in the quarter compared to gains of $127 million in the same period last year.